Joanne Winch
Analyst, Citi
Replay available
Baxter International Inc. (NYSE: BAX) Q3 2025 earnings conference call, held 2025-10-30. Replay captured from the company's public earnings webcast.

Analyst, Citi
Analyst, Goldman Sachs
Analyst, Bank of America Securities
President and Chief Executive Officer, Baxter International
Executive Vice President and Chief Financial Officer, Baxter International
Analyst, Evercore ISI
Vice President, Investor Relations, Baxter International
Analyst, J.P. Morgan
Watch the replay and follow the connected company analysis, news, and investor updates for Baxter International Inc..
WEBVTT 00:00:00.031 -- 00:00:05.116 During the conference, please press star, the zero on your touchtone phone. 00:00:05.116 -- 00:00:10.841 As a reminder, this call is being recorded by Baxter and is copyrighted material. 00:00:10.841 -- 00:00:15.205 It cannot be recorded or rebroadcasted without Baxter's permission. 00:00:15.205 -- 00:00:19.109 If you have any objections, please disconnect at this time. 00:00:19.109 -- 00:00:21.551 I would now like to turn the call over to Mr. 00:00:21.551 -- 00:00:26.455 Kevin Moran, Vice President, Investor Relations at Baxter International. 00:00:26.455 -- 00:00:29.697 Mr. Moran, you may begin. 00:00:30.541 -- 00:00:36.211 Good morning and welcome. Today we'll discuss Baxter's third quarter 2025 00:00:36.211 -- 00:00:41.520 results along with an update to our full year 2025 outlook and newly issued 00:00:41.520 -- 00:00:46.649 fourth quarter 2025 guidance. This morning, a press release was issued 00:00:46.649 -- 00:00:50.268 with our preliminary earnings results and updated outlook. 00:00:50.268 -- 00:00:55.135 The press release and investor presentation are available on the investor section of 00:00:55.135 -- 00:01:00.544 the Baxter website. Joining me today are Andrew Heider, President, Chief Executive 00:01:00.544 -- 00:01:06.152 Officer, and Joel Gratis, Executive Vice President and Chief Financial Officer. 00:01:06.152 -- 00:01:11.380 During the call, we will be making forward-looking statements, including comments regarding 00:01:11.380 -- 00:01:16.809 our financial outlook for the fourth quarter and full year 2025, and matters related 00:01:16.809 -- 00:01:22.206 to future dividend declarations. the anticipated impact of the kidney care sale, 00:01:22.206 -- 00:01:27.271 including our ability to eliminate related costs, t...